# HAIC Combined With Toripalimab and Donafenib for Advanced BTC

> **NCT05350943** · PHASE2 · UNKNOWN · sponsor: **Lu Wang, MD, PhD** · enrollment: 70 (estimated)

## Conditions studied

- Biliary Tract Adenocarcinoma

## Interventions

- **PROCEDURE:** HAIC
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Toripalimab
- **DRUG:** Donafenib

## Key facts

- **NCT ID:** NCT05350943
- **Lead sponsor:** Lu Wang, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2022-11
- **Final completion:** 2023-11
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05350943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05350943, "HAIC Combined With Toripalimab and Donafenib for Advanced BTC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05350943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*